Together, those results indicated that suppressing SOX2 and Nestin signaling by the integrin αvβ3 inhibitor efficiently improved the anticancer effects of the conventional chemotherapeutic agent, providing an innovative approach in glioma therapy. The gene discussed is NES; the disease is central nervous system cancer.